ANEB · Anebulo Pharmaceuticals, Inc. · Executive Compensation
Market Cap
$13.46M
Shares
40.78M
Volume · Mar 2
21.4K
Avg daily vol (3M)
99.57K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Simon Allen | President and Chief Executive Officer | $2,120,841 |
| Kenneth C. Cundy | Chief Scientific Officer | $490,357 |
| Rex Merchant | Chief Financial Officer | $275,000 |
| Daniel Schneeberger | Former President and Chief Executive Officer | $8,797 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Daniel Schneeberger | Former President and Chief Executive Officer | $120,416 |
| Rex Merchant | Chief Financial Officer | $119,792 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Aron R. English | Class I Director | Appointed | 2025-04-07 |
| Richard Anthony Cunningham | Class I Director | Appointed | 2025-04-07 |
| Joseph F. Lawler | Class I Director | Appointed | 2025-04-07 |
| Bimal Shah | member of the Board | Appointed | 2023-10-06 |
| Richard (Richie) Anthony Cunningham | member of the Board | Appointed | 2023-10-06 |
| Richard (Richie) Anthony Cunningham | Chief Executive Officer | Appointed | 2023-10-06 |
| Simon Allen | Board of Directors | Resigned | 2023-10-06 |
| Simon Allen | Chief Executive Officer | Terminated | 2023-10-06 |
| Daniel George | part-time Chief Financial Officer, as well as the Company's principal financial officer and principal accounting officer | Appointed | 2023-09-29 |
| Sandra A. Gardiner | Acting Chief Financial Officer | Resigned | 2023-09-05 |
| Sandra A. Gardiner | principal accounting officer | Appointed | 2023-03-08 |
| Sandra A. Gardiner | Acting Chief Financial Officer | Appointed | 2023-03-08 |